TEL AVIV, Israel, Nov. 9, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, announced that clinical data presented today showed that CM-101 was safe and well-tolerated and achieved reductions in biomarkers associated with lung inflammation and fibrogenesis in a clinical study in patients hospitalized with COVID-19-derived lung injury. CM-101 is a first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein with pro-fibrotic and pro-inflammatory effects. It is in development for the treatment of fibro-inflammatory disorders, including primary sclerosingcholangitis (PSC) and systemic sclerosis (SSc).
HOUSTON, Aug. 12, 2020 (GLOBE NEWSWIRE) -- FibroGenesis, a clinical stage company developing fibroblast based therapeutic solutions for unmet medical needs, announced today new data supporting utilization of its PneumoBlast™ product in treatment of COVID-19. Laboratory experiments comprised of admixing PneumoBlast™ with activated monocyte or endothelial cells demonstrated significant inhibition of tissue factor expression. Tissue factor is the key molecule inducing blood clotting in COVID-19 patients. Monocytes are cells which normally protect the body against pathogens. In the case of COVID-19, monocytes enter the lungs and cause coagulation. Endothelial cells are cells which make up the inside of the blood vessel and regulate substance flow between the bloodstream and surrounding tissues.
HOUSTON, July 2, 2020 /PRNewswire/ -- FibroGenesis announced today identification of molecular mechanisms associated with the potent reduction of lung inflammation previously reported by the Company in an animal model of COVID-19 lung failure.
HOUSTON, May 21, 2020 /PRNewswire/ -- FibroGenesis announced today significant efficacy of its PneumoBlast™ product in an animal model of lung inflammation which resembles COVID-19. Mice immune systems were stimulated to enter hyper-activation mode, which causes symptoms similar to COVID-19. Once COVID-19 simulation was achieved, administration of PneumoBlast™ resulted in significant reduction in lung fluid accumulation. Additionally, reduction was observed from infiltration of inflammatory cells, as well as suppression of chemical mediators such as interleukin-6 (IL-6), which are associated with poor survival in COVID-19 patients.